Author: healthadmin

At the ASCO Annual Meeting, Dana-Farber’s Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial, showing that treatment with daraxone radib, an investigational oral RAS(ON) multiselective inhibitor, significantly increases survival compared to chemotherapy in patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status. Positive results from the pivotal randomized phase 3 RASolute 302 trial comparing daraxone lasib with chemotherapy as second-line therapy for patients with metastatic pancreatic cancer could change the way people think about and treat pancreatic cancer. Results will be presented and simultaneously presented at the plenary session of the American…

Recent research published in journals Psychology of aesthetics, creativity and art We provide evidence that the human brain applies different standards of beauty depending on the type of visual art it evaluates. By comparing the visual properties of historic building facades and artistic paintings, scientists discovered that architects and painters value aesthetic features such as symmetry and complexity in completely different ways. When people look at an image, their evaluation of its beauty depends on several visual variables. These variables include properties such as color, balance, symmetry, complexity, and the relationship between the main subject and its background. Psychological theories…

Detection of light and radiation is essential across the electromagnetic spectrum, but some areas remain particularly challenging. One of these is the terahertz (THz) range, which lies between microwave and infrared radiation. Existing detectors for these frequencies are often slow, lack sensitivity, or rely on large and expensive equipment that frequently requires cryogenic cooling. Researchers have now developed a compact new detector that combines quantum physics and a specially designed metasurface to significantly improve the way terahertz radiation is captured and converted into electrical signals. Their discovery recently advanced photonics. A quantum approach to terahertz detection The new device takes…

An evidence-based analysis of the 2025-2030 DGAs focusing on metabolic health, precision nutrition, and practical MNT implementation for dietitians and researchers.

With a new Phase 3 victory for Erleada (apalutamide), Johnson & Johnson offers a solution to a long-standing gap in prostate cancer treatment. Surgical removal of the prostate (radical prostatectomy) is an important standard treatment, along with radiation therapy, for patients with high-risk localized or locally advanced prostate cancer. However, nearly half of patients who proceed with curative surgery end up having their cancer return, requiring additional treatment and potentially missing out on a potential cure. Additional treatments often intervene only after the cancer has spread, limiting their potential to improve long-term outcomes. This has essentially been the status quo…

This is a moment of truth for Akeso’s ivonescimab, and for many, a make-or-break test for China’s burgeoning biotech industry. And the first-in-class PD-1xVEGF bispecific did not disappoint, at least when it came to the headline message of overall survival. Ivonecimab and chemotherapy resulted in a statistically significant 34% improvement in overall survival (OS), making it the first regimen to exceed the established standard of PD-1 inhibitors and chemotherapy in patients with previously untreated advanced squamous non-small cell lung cancer. The latest overall survival data was generated from an interim analysis of the Phase 3 Harmoni-6 trial conducted in China,…

Excess dietary fructose that is not absorbed in the intestines is associated with increased anxiety and inflammation, according to a combination of human and animal studies. A study published in Brain, Behavior, and Immunity suggests that incomplete fructose digestion can alter the bacterial community in the gastrointestinal tract and trigger an immune response that impacts brain health. Fructose is a simple sugar that occurs naturally in whole fruits and vegetables. Today, it is also added in large quantities to many processed foods, artificial juices, and soft drinks. Historically, humans consumed less than 5 grams of fructose per day for thousands…

Adam Feuerstein is a senior writer and biotechnology columnist, reporting on the intersection of drug development, business, Wall Street, and biotechnology. He is co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. Signal’s Adam can be reached at stataf.54.CHICAGO — Rachna Shroff, a physician and pancreatic cancer expert, was seeing patients at the University of Arizona Cancer Center in April when she heard surprising clinical results about an experimental drug called dalaxone lasib. Patients who took the targeted drug lived almost twice as long as those who received standard chemotherapy. This result…

Angus reports on basic research, clinical science and drug development that have the potential to change survival and quality of life for patients, as well as developments that impact the cancer community. You can access Angus.08 on Signal.CHICAGO — There are usually two standard treatment paths for patients with high-risk prostate cancer that has not spread. The prostate may be surgically removed or a combination of radiation therapy and hormone therapy may be used. Now, following the results of a new phase 3 clinical trial, some oncologists believe a third option may soon be considered. It is a surgery that…

Embargoed: Sunday, May 31st 7am CST / 8am EST Six years after being brought to market as the first targeted therapy for patients with rare genetic tumor mutations, Eli Lilly’s Retevmo (selpercatinib) is solidifying its legacy New study shows ‘dramatic’ results, demonstrating the importance of RET fusion biomarker testing. Retevmo has some broad indications in its name and has long targeted tumors with changes in the rearranged during transfection (RET) gene. However, the early-stage RET fusion-positive non-small cell lung cancer (NSCLC) patient population has yet to realize the major benefits of this push until the arrival of Lilly’s Phase 3…